Publisher： Bentham Science Publishers
E-ISSN： 2212-3873|6|4|313-321
ISSN： 1871-5303
Source： Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol.6, Iss.4, 2006-12, pp. : 313-321
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Pro-inflammatory chemokines are important mediators of inflammation and autoimmune injury. The spatial and temporal expression of chemokines and chemokine receptors in the nephritic kidney suggests that targeting the chemokine system may represent a valuable approach for anti-inflammatory therapy of lupus nephritis. In this review we summarize the available data on the pathogenic role of chemokines and chemokine receptors in lupus nephritis and particularly focus on epidemiological data in lupus patients and interventional studies with chemokine or chemokine receptor antagonists in experimental lupus.
Related content
Animal Models of Lupus and Lupus Nephritis
Current Pharmaceutical Design, Vol. 21, Iss. 18, 2015-06 ,pp. :
Access to resources
Recommend
Leukocyte-mediated Tissue Injury in Ischemic Stroke
Current Medicinal Chemistry, Vol. 21, Iss. 19, 2014-06 ,pp. :
Infliximab: Lupus nephritis: case report
Reactions Weekly, Vol. 1, Iss. 1243, 2009-01 ,pp. :
Etanercept: Lupus nephritis: case report
Reactions Weekly, Vol. 1, Iss. 1216, 2008-01 ,pp. :
Newer Drugs for the Treatment of Lupus Nephritis
Drugs, Vol. 63, Iss. 2, 2003-01 ,pp. :